KR870004710A - 하이드록시프로필 셀룰로오즈 에테르를 함유하는 서방성 조성물 - Google Patents

하이드록시프로필 셀룰로오즈 에테르를 함유하는 서방성 조성물 Download PDF

Info

Publication number
KR870004710A
KR870004710A KR860009683A KR860009683A KR870004710A KR 870004710 A KR870004710 A KR 870004710A KR 860009683 A KR860009683 A KR 860009683A KR 860009683 A KR860009683 A KR 860009683A KR 870004710 A KR870004710 A KR 870004710A
Authority
KR
South Korea
Prior art keywords
weight
hydroxypropyl cellulose
cellulose ether
formulation
pass
Prior art date
Application number
KR860009683A
Other languages
English (en)
Other versions
KR920000737B1 (ko
Inventor
알더만 다니엔에이.
Original Assignee
리차드 지. 워터맨
더 다우 케미칼 캄파다
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25174902&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR870004710(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 리차드 지. 워터맨, 더 다우 케미칼 캄파다 filed Critical 리차드 지. 워터맨
Publication of KR870004710A publication Critical patent/KR870004710A/ko
Application granted granted Critical
Publication of KR920000737B1 publication Critical patent/KR920000737B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • General Preparation And Processing Of Foods (AREA)

Abstract

내용 없음

Description

하이드록시프로필 셀룰로오즈 에테르를 함유하는 서방성 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (21)

  1. 적어도 하나의 활성 성분; 미세한 입자 크기를 갖는 하이드록시프로필 셀룰로오즈 에테르: 임의로, 친수성 클로이드 및 임의로 하나 이상의 담체 또는 부형제로 이루어지는 고형의 약체학적 제형.
  2. 제1항에 있어서, 정제 형태인 제형.
  3. 제1항에 있어서, 셀룰로오즈 에테르 입자의 적어도 50중량%가 -100메쉬체를 통과할 수 있는 제형.
  4. 제1항에 있어서, 친수성 콜로이드가 4내지 12중량%의 하이드록시프로폭실 함량 및 19내지 30중량%의 메톡실 함량을 가지며 400내지 100,000cps의 2% 수용액점도를 갖는 하이드록실프로필 메틸셀룰로오즈 에테르인 제형.
  5. 제4항에 있어서, 하이드록시프로필 셀룰로오즈 에테르가 하이드록시프로필 셀룰로오즈 에테르와 하이드록시프로필 메틸셀룰로오즈 에테르의 배합 중량의 약 30중량%를 차지하는 제형.
  6. 제5항에 있어서, 하이드록시프로필 셀룰로오즈 에테르 입자의 적어도 50중량%가 - 100메쉬체를 통과할 수 있고, 하이드록시 프로필 메틸-셀룰로오즈 에테르 입자의 적어도 70중량%는 - 100메쉬체를 통과할 수 있는 제형.
  7. 제6항에 있어서, 하이드록시프로필 셀룰로오즈 에테르 입자의 적어도 50중량%가 - 100메쉬체를 통과할 수 있고, 하이드록시프로필 메틸셀룰로오즈 에테르 입자의 적어도 70중량%는 - 140메쉬 체를 통과할 수 있는 제형.
  8. 제1항에 있어서, 하이드록시프로필 셀룰로오즈 에테르가 20 내지 80중량%의 하이드록시프로폭실 치환도를 갖는 제형.
  9. 제1항에 있어서, 하이드록시프로필 셀룰로오즈 에테르의 양이 5 내지 90중량%인 제형.
  10. 제9항에 있어서, 친수성 콜로이드의 양이 5 내지 75중량%인 제형.
  11. 적어도 하나의 활성 성분 : 미세 입자크기를 갖는 하이드록시프로필 셀룰로오즈 에테르 : 임의로, 친수성 콜로이드 : 및 임의로, 하나이상의 담체 또는 부형제를 분말 형태로 함께 혼합하여 균질혼합물을 수득함을 특징으로 하여, 약제학적 제형을 제조하는 방법.
  12. 제11항에 있어서, 하이드록시프로필 셀룰로오즈 에테르를, 프로필렌옥사이드와 알칼리 셀룰로오즈를 반응시켜 제조하는 방법.
  13. 제11항에 있어서, 셀룰로오즈 에테르 입자의 적어도 50중량%가 - 100메쉬체를 통과할 수 있는 방법.
  14. 제11항에 있어서, 친수성 콜로이드가 4내지 12중량%의 하이드록시프로폭실 함량 및 19내지 30중량%의 메톡실함량을 가지며 400내지 100,000cps의 2% 수용액점도를 갖는 하이드록시프로필 셀룰로오즈인 방법.
  15. 제14항에 있어서, 하이드록시프로필 셀룰로오즈 에테르가 하이드록시프로필 셀룰로오즈 에테르 및 하이드록시 프로필 메틸셀룰로오즈 에테르의 배합 중량의 적어도 양 30중량%를 차지하는 방법.
  16. 제15항에 있어서, 하이드록시프로필 셀룰로오즈에테르 입자의 적어도 50중량%가 - 100메쉬 를 통과할 수 있고, 하이드록시프로필 메틸셀룰로오즈 에테르 입자의 적어도 70중량%는 - 100메쉬 체를 통과할 수 있는 방법.
  17. 제16항에 있어서, 하이드록시프로필 셀룰로오즈에테르 입자의 적어도 50중량%가 - 100메쉬 체를 통과할 수 있고, 하이드록시프로필 메틸셀룰로오즈 에테르 입자의 적어도 70중량%는 - 140메쉬 체를 통과할 수 있는 방법.
  18. 제11항에 있어서, 하이드록시프로필 셀룰로오즈 에테르가 20 내지 80중량%의 하이드록시 프로폭실 치환도을 갖는 방법.
  19. 제11항에 있어서, 하이드록시프로필 셀룰로오즈 에테르의 양이 5 내지 90중량%인 방법.
  20. 제19항에 있어서, 친수성 콜로이드의 양이 5 내지 75중량%인 방법.
  21. 제11항에 있어서, 제형에 1000내지 6000psi(6.9 내지 41.4MPa)의 압력을 가하여 정제를 제조 하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019860009683A 1985-11-18 1986-11-17 하이드록시프로필 셀룰로오즈 에테르를 함유하는 서방성 고형 제형 KR920000737B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/799,044 US4704285A (en) 1985-11-18 1985-11-18 Sustained release compositions comprising hydroxypropyl cellulose ethers
US799044 1985-11-18

Publications (2)

Publication Number Publication Date
KR870004710A true KR870004710A (ko) 1987-06-01
KR920000737B1 KR920000737B1 (ko) 1992-01-21

Family

ID=25174902

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860009683A KR920000737B1 (ko) 1985-11-18 1986-11-17 하이드록시프로필 셀룰로오즈 에테르를 함유하는 서방성 고형 제형

Country Status (12)

Country Link
US (1) US4704285A (ko)
EP (1) EP0223590B2 (ko)
JP (1) JPH078809B2 (ko)
KR (1) KR920000737B1 (ko)
AT (1) ATE91232T1 (ko)
AU (1) AU599058B2 (ko)
BR (1) BR8606003A (ko)
CA (1) CA1287582C (ko)
DE (1) DE3688674T2 (ko)
DK (1) DK175298B1 (ko)
FI (1) FI90310C (ko)
PH (1) PH23698A (ko)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1191674B (it) * 1986-03-07 1988-03-23 Eurand Spa Formulazioni per la preparazione di farmaci a rilascio prolungato adatte alla somministrazione per via orale
EP0297866A3 (en) * 1987-07-01 1989-12-13 The Boots Company PLC Therapeutic agents
US4994276A (en) * 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
US5271946A (en) * 1988-04-20 1993-12-21 Asta Pharma Aktiengesellschaft Controlled release azelastine-containing pharmaceutical compositions
WO1989010745A1 (en) * 1988-05-02 1989-11-16 Pomerantz, Edwin Compositions and in situ methods for forming films on body tissue
US4880636A (en) * 1988-05-13 1989-11-14 Franz Robert M Film coated tablet of ranitidine HCl
US5169639A (en) * 1988-09-19 1992-12-08 Edward Mendell Co., Inc. Controlled release verapamil tablets
US5128143A (en) * 1988-09-19 1992-07-07 Edward Mendell Co., Inc. Sustained release excipient and tablet formulation
US5135757A (en) * 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
NZ230763A (en) * 1988-09-27 1991-10-25 Takeda Chemical Industries Ltd Production of granules having a core by spraying the cores with a dispersion of hydroxypropylcellulose, optionally incorporating an active ingredient
US5268181A (en) * 1989-04-13 1993-12-07 Upsher-Smith Laboratories, Inc. Method of using niacin to control nocturnal cholesterol synthesis
US5175003A (en) * 1990-04-06 1992-12-29 Biosytes Usa, Inc. Dual mechanism controlled release system for drug dosage forms
US5576306A (en) * 1991-03-01 1996-11-19 Dow Chemical Company Pharmaceutical compositions and uses of water-soluble, high-viscosity grade cellulose ethers
US5721221A (en) * 1991-03-08 1998-02-24 Regents Of The University Of Minnesota Lowering blood cholesterol levels using water soluble cellulose ethers
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5281584A (en) * 1992-02-28 1994-01-25 The Dow Chemical Company Effect of particle-size distribution of cellulose ethers on palatability of compositions
US5472711A (en) * 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
HU226456B1 (en) * 1992-09-18 2008-12-29 Astellas Pharma Inc Sustained-release hydrogel preparation
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US5451409A (en) * 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
US5728402A (en) * 1994-11-16 1998-03-17 Andrx Pharmaceuticals Inc. Controlled release formulation of captopril or a prodrug of captopril
US6103263A (en) * 1994-11-17 2000-08-15 Andrx Pharmaceuticals, Inc. Delayed pulse release hydrogel matrix tablet
US5736159A (en) * 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
CA2173818A1 (fr) * 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
JP2001507359A (ja) * 1997-01-03 2001-06-05 エラン コーポレーション ピーエルシー 徐放性シサプリドミニ錠剤製剤
US7179486B1 (en) 1997-04-01 2007-02-20 Nostrum Pharmaceuticals, Inc. Process for preparing sustained release tablets
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
FR2766708B1 (fr) 1997-07-30 2000-05-05 Galenix Dev Composition contenant de l'hydroxypropylcellulose, de l'hydroxypropylmethylcellulose et/ou de l'ethylcellullose a titre d'agents desintegrants, et procede d'obtention
FR2766707A1 (fr) * 1997-07-30 1999-02-05 Galenix Dev Composition contenant de l'hydroxypropylcellulose, de l'hydroxypropylmethyl-cellulose et/ou de l'ethylcellulose a titre d'agents desintegrants, et procede d'obtention
IN186245B (ko) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US5948440A (en) * 1997-12-17 1999-09-07 Ranbaxy Laboratories Limited Modified release matrix formulation of cefaclor and cephalexin
KR100620935B1 (ko) 1998-03-19 2006-09-13 브리스톨-마이어스스퀴브컴파니 용해도가 높은 약물에 대한 2상 서방성 전달 시스템과 방법
JP2000119181A (ja) * 1998-10-06 2000-04-25 Kureha Chem Ind Co Ltd エスクレチン及びその誘導体の放出制御経口製剤
US20020169145A1 (en) * 1998-10-14 2002-11-14 Rajen Shah Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
ATE424810T1 (de) 1998-12-11 2009-03-15 Nostrum Pharmaceuticals Inc Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
US6180682B1 (en) 1999-01-26 2001-01-30 Virgil A. Place Buccal drug delivery system for use in male contraception
US6284262B1 (en) 1999-01-26 2001-09-04 Virgil A. Place Compact dosage unit for buccal administration of a pharmacologically active agent
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
IN190974B (ko) 1999-09-10 2003-09-06 Ranbaxy Lab Ltd
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7838032B2 (en) 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US6372252B1 (en) 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6881420B2 (en) * 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
EP1556014A1 (en) * 2002-10-22 2005-07-27 Ranbaxy Laboratories, Ltd. Sustained release compositions containing alfuzosin
US20040086566A1 (en) * 2002-11-04 2004-05-06 Alpharma, Inc. Waxy matrix dosage forms
US20040175423A1 (en) * 2003-02-05 2004-09-09 Daniella Licht Sustained release formulation of N- (2-propylpentanoyl) glycinamide and related compounds
ITMI20031096A1 (it) * 2003-05-30 2004-11-30 Eurand Spa Microcapsule per coacervazione contenenti farmaco incorporato nel polimero di rivestimento
EP2112920B1 (en) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
EP1675576A1 (en) * 2003-10-03 2006-07-05 LifeCycle Pharma A/S A method for preparing modified release pharmaceutical compositions
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
EP2471536A1 (en) 2004-09-29 2012-07-04 Harbor BioSciences, Inc. Steroid analogs and characterization and treatment methods
AR052225A1 (es) * 2004-11-04 2007-03-07 Astrazeneca Ab Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
MX2007006233A (es) 2004-11-24 2007-11-23 Medpointe Healthcare Inc Composiciones que comprenden azelastina y metodos de uso de la misma.
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US20060134210A1 (en) * 2004-12-22 2006-06-22 Astrazeneca Ab Solid dosage form comprising proton pump inhibitor and suspension made thereof
NZ567766A (en) 2005-11-11 2012-04-27 V Ravi Chandran Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
JP5457830B2 (ja) 2006-04-03 2014-04-02 オディディ，イサ オルガノゾル被膜を含む制御放出送達デバイス
KR101082774B1 (ko) * 2006-04-12 2011-11-11 닛뽕소다 가부시키가이샤 서방성 정제의 제조 방법
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20070269512A1 (en) * 2006-05-22 2007-11-22 Wang Wenhua W Gastroretentive sustained release formulations
US20090082315A1 (en) * 2007-09-05 2009-03-26 Raif Tawakol Compositions and Methods for Controlling Cholesterol Levels
ES2436850T3 (es) 2009-08-31 2014-01-07 Zeria Pharmaceutical Co., Ltd. Comprimido para administración oral para lavado intestinal
TR200908308A1 (tr) 2010-01-18 2011-08-22 Turgut İlaçlari A.Ş. Etodolak içeren sürekli salım tablet formulasyonu
WO2012037358A1 (en) 2010-09-16 2012-03-22 The University Of North Carolina At Chapel Hill Asymmetric bifunctional silyl monomers and particles thereof as prodrugs and delivery vehicles for pharmaceutical, chemical and biological agents
JP2013087170A (ja) * 2011-10-17 2013-05-13 Nippon Soda Co Ltd ヒドロキシプロピルセルロース微粒子
WO2013082111A2 (en) 2011-11-29 2013-06-06 The University Of North Carolina At Chapel Hill Geometrically engineered particles and methods for modulating macrophage or immune responses
EP3364955B1 (en) 2015-10-09 2022-04-20 RB Health (US) LLC Pharmaceutical formulation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2050701C3 (de) * 1969-10-17 1979-12-20 Shinetsu Chemical Co., Tokio Verwendung eines pulverförmigen Celluloseäthers als Hilfsstoff zur Herstellung von leicht zerfallbaren festen Arzneiformen
US3852421A (en) * 1970-03-23 1974-12-03 Shinetsu Chemical Co Excipient and shaped medicaments prepared therewith
JPS4917565B1 (ko) * 1970-12-29 1974-05-01
GB1405088A (en) * 1971-06-03 1975-09-03 Mundipharma Ag Slow release formulation
US3951821A (en) * 1972-07-14 1976-04-20 The Dow Chemical Company Disintegrating agent for tablets
JPS5438167B2 (ko) * 1974-04-27 1979-11-19
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
JPS5163927A (en) * 1974-11-28 1976-06-02 Shinetsu Chemical Co Ketsugoseiryokonajozaihokaizaino seizohoho
JPS5474855A (en) * 1977-11-29 1979-06-15 Takeda Chem Ind Ltd Preparation of finely divided soluble cellulose derivative
US4269859A (en) * 1979-04-19 1981-05-26 Brown Company Cellulose floc granules and process
JPS5657719A (en) * 1979-10-16 1981-05-20 Asahi Chem Ind Co Ltd Preparation of pharmaceutical
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4556678A (en) * 1982-06-24 1985-12-03 Key Pharmaceuticals, Inc. Sustained release propranolol tablet
JPS59193815A (ja) * 1983-04-15 1984-11-02 Daicel Chem Ind Ltd 錠剤の製法
US4680323A (en) * 1983-12-01 1987-07-14 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
ES8801121A1 (es) * 1985-02-19 1988-01-01 Key Pharma Procedimiento de fabricacion de una unidad de dosificacion para la administracion oral de cloruro potasico.

Also Published As

Publication number Publication date
US4704285A (en) 1987-11-03
FI864665A0 (fi) 1986-11-17
DK175298B1 (da) 2004-08-16
DK551486D0 (da) 1986-11-18
FI90310B (fi) 1993-10-15
EP0223590A2 (en) 1987-05-27
CA1287582C (en) 1991-08-13
KR920000737B1 (ko) 1992-01-21
AU599058B2 (en) 1990-07-12
EP0223590A3 (en) 1987-11-25
FI864665A (fi) 1987-05-19
ATE91232T1 (de) 1993-07-15
DK551486A (da) 1987-05-19
AU6504686A (en) 1987-05-21
PH23698A (en) 1989-09-27
EP0223590B2 (en) 1996-09-11
EP0223590B1 (en) 1993-07-07
DE3688674D1 (de) 1993-08-12
JPS62120323A (ja) 1987-06-01
FI90310C (fi) 1994-01-25
DE3688674T2 (de) 1993-10-14
JPH078809B2 (ja) 1995-02-01
BR8606003A (pt) 1987-09-15

Similar Documents

Publication Publication Date Title
KR870004710A (ko) 하이드록시프로필 셀룰로오즈 에테르를 함유하는 서방성 조성물
FI100219B (fi) Menetelmä farmaseuttisen granulaatin valmistamiseksi
KR870003781A (ko) 지효성 조성물
SE8404804D0 (sv) Forfarande for framstellning av farmaceutiska kompositioner med fordrojd frigoring och med en hog halt aktiv bestandsdel
KR880000089A (ko) 서방형 약제 조성물
ES350409A1 (es) Un metodo para producir un material organico insoluble en agua y dispersable en la misma.
EP0277092A1 (de) Therapeutisches System für schwerlösliche Wirkstoffe
EP0278464A1 (en) Cholestyramine composition and process for its preparation
LU86966A1 (fr) Orales therapeutisches system mit systemischer wirkung
DK624287A (da) Komprimeret tablet eller kapsel
KR880701551A (ko) 제약적 처방
AR016827A1 (es) PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
IL43022A (en) Pharmaceutical preparation for oral use containing cholestyramine quercet
KR910011241A (ko) 정제로 직접 압착 가능한 약제학적 분말 조성물을 제조하기 위한 분무 건조법
DE50009804D1 (de) Vernetzerfreie zubereitungen
Preethi et al. Recent trends of polymer usage in the formulation of orodispersible tablets
AR001349A1 (es) Nueva composición farmacéutica que contiene trimebutina y proceso para su preparación.
KR970704447A (ko) 푸시드산 정제의 제조방법(Preparation of fusidic acid tablets)
JPH05507651A (ja) 放出可能な状態で結合された活性物質
MY100210A (en) Sustained release compositions comprising hydroxypropyl cellulose ethers.
JPS6490134A (en) Laxative composition
US2864744A (en) Penicillin in solid dosage unit form
TH4261EX (th) สารผสมช่วยเสริมการปลดปล่อยซึ่งประกอบด้วยไฮดรอกซิโพรพิลเซลลูโลสอีเธอร์
US2816058A (en) Laxative composition containing albedo
Shinkar et al. Superdisintegrants: A Review

Legal Events

Date Code Title Description
A201 Request for examination
E601 Decision to refuse application
E902 Notification of reason for refusal
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20051212

Year of fee payment: 15

EXPY Expiration of term